Stay updated on Milademetan Safety in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.

Latest updates to the Milademetan Safety in AML/MDS Clinical Trial page
- ChecktodayChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedAdded Acute myeloid leukemia as a listed condition/keyword on the study page.SummaryDifference0.0%

- Check29 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.0%

- Check36 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check65 days agoChange DetectedAdded Revision: v3.4.2 to the page; Removed the older funding notice (v3.4.1). These changes do not modify the study content, eligibility, endpoints, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedA site-wide notice about a lapse in government funding and an update from version v3.4.0 to v3.4.1 was added to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Milademetan Safety in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.